It	O
is	O
recommended	O
that	O
if	O
CASODEX	B-Drug
is	O
started	O
in	O
patients	O
already	O
receiving	O
coumarin	O
anticoagulants	O
,	O
prothrombin	O
times	O
should	O
be	O
closely	O
monitored	O
and	O
adjustment	O
of	O
the	O
anticoagulant	O
dose	O
may	O
be	O
necessary	O
.	O

No	O
Information	O
Provided	O
Drug	O
Interactions	O
:	O
The	O
central	O
anticholinergic	O
syndrome	O
can	O
occur	O
when	O
anticholinergic	O
agents	O
such	O
as	O
AKINETON	B-Drug
are	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
have	O
secondary	O
anticholinergic	O
actions	O
,	O
e.g.	O
,	O
certain	O
narcotic	O
analgesics	O
such	O
as	O
meperidine	B-Drug
,	O
the	O
phenothiazines	O
and	O
other	O
antipsychotics	O
,	O
tricyclic	O
antidepressants	O
,	O
certain	O
antiarrhythmics	O
such	O
as	O
the	O
quinidine	B-Drug
salts	O
,	O
and	O
antihistamines	O
.	O

ZEBETA	B-Drug
should	O
not	O
be	O
combined	O
with	O
other	O
beta-blocking	O
agents	O
.	O

Patients	O
receiving	O
catecholamine-depleting	O
drugs	O
,	O
such	O
as	O
reserpine	B-Drug
or	O
guanethidine	B-Drug
,	O
should	O
be	O
closely	O
monitored	O
,	O
because	O
the	O
added	O
beta-adrenergic	O
blocking	O
action	O
of	O
ZEBETA	B-Drug
may	O
produce	O
excessive	O
reduction	O
of	O
sympathetic	O
activity	O
.	O

In	O
patients	O
receiving	O
concurrent	O
therapy	O
with	O
clonidine	B-Drug
,	O
if	O
therapy	O
is	O
to	O
be	O
discontinued	O
,	O
it	O
is	O
suggested	O
that	O
ZEBETA	B-Drug
be	O
discontinued	O
for	O
several	O
days	O
before	O
the	O
withdrawal	O
of	O
clonidine	B-Drug
.	O

ZEBETA	B-Drug
should	O
be	O
used	O
with	O
care	O
when	O
myocardial	O
depressants	O
or	O
inhibitors	O
of	O
AV	O
conduction	O
,	O
such	O
as	O
certain	O
calcium	O
antagonists	O
(	O
particularly	O
of	O
the	O
phenylalkylamine	O
[	O
verapamil	B-Drug
]	O
and	O
benzothiazepine	O
[	O
diltiazem	B-Drug
]	O
classes	O
)	O
,	O
or	O
antiarrhythmic	O
agents	O
,	O
such	O
as	O
disopyramide	B-Drug
,	O
are	O
used	O
concurrently	O
.	O

Concurrent	O
use	O
of	O
rifampin	B-Drug
increases	O
the	O
metabolic	O
clearance	O
of	O
ZEBETA	B-Drug
,	O
resulting	O
in	O
a	O
shortened	O
elimination	O
half-life	O
of	O
ZEBETA	B-Drug
.	O

However	O
,	O
initial	O
dose	O
modification	O
is	O
generally	O
not	O
necessary	O
.	O

Pharmacokinetic	O
studies	O
document	O
no	O
clinically	O
relevant	O
interactions	O
with	O
other	O
agents	O
given	O
concomitantly	O
,	O
including	O
thiazide	O
diuretics	O
,	O
digoxin	B-Drug
,	O
and	O
cimetidine	B-Drug
.	O

There	O
was	O
no	O
effect	O
of	O
ZEBETA	B-Drug
on	O
prothrombin	O
time	O
in	O
patients	O
on	O
stable	O
doses	O
of	O
warfarin	B-Drug
.	O

Risk	O
of	O
Anaphylactic	O
Reaction	O
:	O
While	O
taking	O
beta-blockers	O
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reactions	O
.	O

Use	O
of	O
MAO	O
inhibitors	O
may	O
cause	O
an	O
excessive	O
increase	O
in	O
blood	O
pressure	O
and	O
heart	O
stimulation	O
.	O

If	O
you	O
are	O
also	O
using	O
a	O
steroid	O
inhaler	O
,	O
take	O
bitolterol	B-Drug
first	O
and	O
then	O
wait	O
about	O
15	O
minutes	O
before	O
using	O
the	O
steroid	O
inhaler	O
.	O

This	O
allows	O
bitolterol	B-Drug
to	O
open	O
air	O
passages	O
,	O
increasing	O
the	O
effectiveness	O
of	O
the	O
steroid	O
.	O

Angiomax	B-Drug
does	O
not	O
exhibit	O
binding	O
to	O
plasma	O
proteins	O
(	O
other	O
than	O
thrombin	O
)	O
or	O
red	O
blood	O
cells	O
.	O

In	O
clinical	O
trials	O
in	O
patients	O
undergoing	O
PTCA/PCI	O
,	O
co-administration	O
of	O
Angiomax	B-Drug
with	O
heparin	B-Drug
,	O
warfarin	B-Drug
,	O
thrombolytics	O
or	O
glycoprotein	O
IIb/IIIa	O
inhibitors	O
was	O
associated	O
with	O
increased	O
risks	O
of	O
major	O
bleeding	O
events	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
medications	O
.	O

There	O
is	O
no	O
experience	O
with	O
co-administration	O
of	O
Angiomax	B-Drug
and	O
plasma	O
expanders	O
such	O
as	O
dextran	B-Drug
.	O

Angiomax	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
disease	O
states	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bleeding	O
.	O

Immunogenicity/Re-exposure	O
:	O
In	O
in	O
vitro	O
studies	O
,	O
Angiomax	B-Drug
exhibited	O
no	O
platelet	O
aggregation	O
response	O
against	O
sera	O
from	O
patients	O
with	O
a	O
history	O
of	O
HIT/HITTS	O
.	O

Among	O
494	O
subjects	O
who	O
received	O
Angiomax	B-Drug
in	O
clinical	O
trials	O
and	O
were	O
tested	O
for	O
antibodies	O
,	O
2	O
subjects	O
had	O
treatment-emergent	O
positive	O
bivalirudin	B-Drug
antibody	O
tests	O
.	O

Neither	O
subject	O
demonstrated	O
clinical	O
evidence	O
of	O
allergic	O
or	O
anaphylactic	O
reactions	O
and	O
repeat	O
testing	O
was	O
not	O
performed	O
.	O

Nine	O
additional	O
patients	O
who	O
had	O
initial	O
positive	O
tests	O
were	O
negative	O
on	O
repeat	O
testing	O
.	O

Certain	O
antibiotic	O
,	O
cisplatin	B-Drug
,	O
cyclosporine	B-Drug
,	O
diuretic	O
,	O
foscarnet	B-Drug
,	O
and	O
vaccines	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
VELCADE	B-Drug
.	O

In	O
vitro	O
studies	O
with	O
human	O
liver	O
microsomes	O
indicate	O
that	O
bortezomib	B-Drug
is	O
primarily	O
a	O
substrate	O
for	O
cytochrome	O
P450	O
3A4	O
,	O
2C19	O
,	O
and	O
1A2	O
.	O

Patients	O
who	O
are	O
concomitantly	O
receiving	O
VELCADE	B-Drug
and	O
drugs	O
that	O
are	O
inhibitors	O
or	O
inducers	O
of	O
cytochrome	O
P450	O
3A4	O
should	O
be	O
closely	O
monitored	O
for	O
either	O
toxicities	O
or	O
reduced	O
efficacy	O
.	O

During	O
clinical	O
trials	O
,	O
hypoglycemia	O
and	O
hyperglycemia	O
were	O
reported	O
in	O
diabetic	O
patients	O
receiving	O
oral	O
hypoglycemics	O
.	O

Patients	O
on	O
oral	O
antidiabetic	O
agents	O
receiving	O
VELCADE	B-Drug
treatment	O
may	O
require	O
close	O
monitoring	O
of	O
their	O
blood	O
glucose	O
levels	O
and	O
adjustment	O
of	O
the	O
dose	O
of	O
their	O
antidiabetic	O
medication	O
.	O

Drug	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

Bosentan	B-Drug
is	O
metabolized	O
by	O
CYP2C9	O
and	O
CYP3A4	O
.	O

Inhibition	O
of	O
these	O
isoenzymes	O
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
bosentan	B-Drug
.	O

Bosentan	B-Drug
is	O
an	O
inducer	O
of	O
CYP3A4	O
and	O
CYP2C9	O
.	O

Consequently	O
,	O
plasma	O
concentrations	O
of	O
drugs	O
metabolized	O
by	O
these	O
two	O
isoenzymes	O
will	O
be	O
decreased	O
when	O
TRACLEER	B-Drug
is	O
co-administered	O
.	O


Fluoxetine	B-Drug
and	O
its	O
active	O
metabolite	O
,	O
norfluoxe-tine	O
,	O
have	O
long	O
half-lives	O
(	O
4	O
to	O
16	O
days	O
for	O
norfluoxetine	B-Drug
)	O
,	O
that	O
may	O
affect	O
strategies	O
during	O
conversion	O
from	O
one	O
drug	O
to	O
the	O
other	O
.	O

Administration	O
of	O
reserpine	B-Drug
during	O
therapy	O
with	O
a	O
tricyclic	O
antidepressant	O
has	O
been	O
shown	O
to	O
produce	O
a	O
stimulating	O
effect	O
in	O
some	O
depressed	O
patients	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
the	O
dosage	O
are	O
required	O
when	O
nortriptyline	B-Drug
hydrochloride	I-Drug
is	O
used	O
with	O
other	O
anticholinergic	O
drugs	O
or	O
sympathomimetic	O
drugs	O
.	O

The	O
patient	O
should	O
be	O
informed	O
that	O
the	O
response	O
to	O
alcohol	B-Drug
may	O
be	O
exaggerated	O
.	O

Drugs	O
Metabolized	O
by	O
P450IID6	O
A	O
subset	O
(	O
3	O
%	O
to	O
10	O
%	O
)	O
of	O
the	O
population	O
has	O
reduced	O
activity	O
of	O
certain	O
drug	O
metabolizing	O
enzymes	O
such	O
as	O
the	O
cytochrome	O
P450	O
isoenzyme	O
P450IID6	O
.	O

Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	O
such	O
as	O
debrisoquin	B-Drug
,	O
dextromethorphan	B-Drug
,	O
and	O
the	O
tricyclic	O
antidepressants	O
.	O

These	O
individuals	O
may	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	O
antidepressants	O
when	O
given	O
usual	O
doses	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
including	O
many	O
antidepressants	O
(	O
tricyclic	O
antidepressants	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
,	O
and	O
others	O
)	O
,	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isoenzyme	O
,	O
and	O
thus	O
may	O
make	O
normal	O
metab-olizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
system	O
,	O
leading	O
to	O
drug	O
interactions	O
.	O

Concomitant	O
use	O
of	O
tricyclic	O
antidepressants	O
with	O
other	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450IID6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	O
antidepressant	O
or	O
the	O
other	O
drug	O
.	O

Therefore	O
,	O
co-administration	O
of	O
tricyclic	O
antidepressants	O
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
including	O
other	O
antidepressants	O
,	O
phenothiazines	O
,	O
carbamazepine	B-Drug
,	O
and	O
Type	O
1C	O
antiarrhythmics	O
(	O
eg	O
,	O
propafenone	B-Drug
,	O
flecainide	B-Drug
,	O
and	O
encainide	B-Drug
)	O
,	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
eg	O
,	O
quinidine	B-Drug
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Animal	O
toxicology	O
studies	O
showed	O
increased	O
DEET	B-Drug
toxicity	O
when	O
DEET	B-Drug
was	O
included	O
as	O
proof	O
of	O
the	O
formulation	O
.	O

Although	O
there	O
was	O
no	O
clinical	O
evidence	O
in	O
the	O
vehicle-controlled	O
studies	O
of	O
drug	O
interactions	O
with	O
systemic	O
antiretroviral	O
agents	O
,	O
including	O
protease	O
inhibitors	O
,	O
macrolide	O
antibiotics	O
,	O
and	O
azole	O
antifungals	O
,	O
the	O
effect	O
of	O
Panretin	B-Drug
gel	O
on	O
the	O
steady-state	O
concentrations	O
of	O
these	O
drugs	O
is	O
not	O
known	O
.	O

No	O
drug	O
interaction	O
data	O
are	O
available	O
on	O
concomitant	O
administration	O
of	O
Panretin	B-Drug
gel	O
and	O
systemic	O
anti-KS	O
agents	O
.	O

The	O
following	O
drug	O
interactions	O
were	O
observed	O
in	O
some	O
patients	O
undergoing	O
treatment	O
with	O
oral	O
allopurinol	B-Drug
.	O

Although	O
the	O
pattern	O
of	O
use	O
for	O
oral	O
allopurinol	B-Drug
includes	O
longer	O
term	O
therapy	O
,	O
particularly	O
for	O
gout	O
and	O
renal	O
calculi	O
,	O
the	O
experience	O
gained	O
may	O
be	O
relevant	O
.	O

Mercaptopurine/Azathioprine	B-Drug
:	O
Allopurinol	O
inhibits	O
the	O
enzymatic	O
oxidation	O
of	O
mercaptopurine	O
and	O
azathioprine	O
to	O
6-thiouric	O
acid	O
.	O

This	O
oxidation	O
,	O
which	O
is	O
catalyzed	O
by	O
xanthine	O
oxidase	O
,	O
inactivates	O
mercaptopurine	B-Drug
.	O

In	O
patients	O
receiving	O
mercaptopurine	B-Drug
(	O
Purinethol	B-Drug
)	O
or	O
azathioprine	B-Drug
(	O
Imuran	B-Drug
)	O
,	O
the	O
concomitant	O
administration	O
of	O
300-600	O
mg	O
of	O
allopurinol	B-Drug
per	O
day	O
will	O
require	O
a	O
reduction	O
in	O
dose	O
to	O
approximately	O
one-third	O
to	O
one-fourth	O
of	O
the	O
usual	O
dose	O
of	O
mercaptopurine	B-Drug
or	O
azathioprine	B-Drug
.	O

Subsequent	O
adjustment	O
of	O
doses	O
of	O
mercaptopurine	B-Drug
or	O
azathioprine	B-Drug
should	O
be	O
made	O
on	O
the	O
basis	O
of	O
therapeutic	O
response	O
and	O
the	O
appearance	O
of	O
toxic	O
effects	O
.	O

Dicumarol	B-Drug
:	O
It	O
has	O
been	O
reported	O
that	O
allopurinol	B-Drug
prolongs	O
the	O
half-life	O
of	O
the	O
anticoagulant	O
,	O
dicumarol	B-Drug
.	O

The	O
clinical	O
basis	O
of	O
this	O
drug	O
interaction	O
has	O
not	O
been	O
established	O
but	O
should	O
be	O
noted	O
when	O
allopurinol	B-Drug
is	O
given	O
to	O
patients	O
already	O
on	O
dicumarol	B-Drug
therapy	O
.	O

Consequently	O
,	O
prothrombin	O
time	O
should	O
be	O
reassessed	O
periodically	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O

Uricosuric	O
Agents	O
:	O
Since	O
the	O
excretion	O
of	O
oxipurinol	B-Drug
is	O
similar	O
to	O
that	O
of	O
urate	O
,	O
uricosuric	O
agents	O
,	O
which	O
increase	O
the	O
excretion	O
of	O
urate	O
,	O
are	O
also	O
likely	O
to	O
increase	O
the	O
excretion	O
of	O
oxipurinol	B-Drug
and	O
thus	O
lower	O
the	O
degree	O
of	O
inhibition	O
of	O
xanthine	O
oxidase	O
.	O

The	O
concomitant	O
administration	O
of	O
uricosuric	O
agents	O
and	O
allopurinol	B-Drug
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
excretion	O
of	O
oxypurines	O
(	O
hypoxanthine	O
and	O
xanthine	O
)	O
and	O
an	O
increase	O
in	O
urinary	O
uric	O
acid	O
excretion	O
compared	O
with	O
that	O
observed	O
with	O
allopurinol	B-Drug
alone	O
.	O

Although	O
clinical	O
evidence	O
to	O
date	O
has	O
not	O
demonstrated	O
renal	O
precipitation	O
of	O
oxypurines	O
in	O
patients	O
either	O
on	O
allopurinol	B-Drug
alone	O
or	O
in	O
combination	O
with	O
uricosuric	O
agents	O
,	O
the	O
possibility	O
should	O
be	O
kept	O
in	O
mind	O
.	O

Thiazide	O
Diuretics	O
:	O
The	O
reports	O
that	O
the	O
concomitant	O
use	O
of	O
allopurinol	B-Drug
and	O
thiazide	O
diuretics	O
may	O
contribute	O
to	O
the	O
enhancement	O
of	O
allopurinol	B-Drug
toxicity	O
in	O
some	O
patients	O
have	O
been	O
reviewed	O
in	O
an	O
attempt	O
to	O
establish	O
a	O
cause-and-effect	O
relationship	O
and	O
a	O
mechanism	O
of	O
causation	O
.	O

Review	O
of	O
these	O
case	O
reports	O
indicates	O
that	O
the	O
patients	O
were	O
mainly	O
receiving	O
thiazide	O
diuretics	O
for	O
hypertension	O
and	O
that	O
tests	O
to	O
rule	O
out	O
decreased	O
renal	O
function	O
secondary	O
to	O
hypertensive	O
nephropathy	O
were	O
not	O
often	O
performed	O
.	O

In	O
those	O
patients	O
in	O
whom	O
renal	O
insufficiency	O
was	O
documented	O
,	O
however	O
,	O
the	O
recommendation	O
to	O
lower	O
the	O
dose	O
of	O
allopurinol	B-Drug
was	O
not	O
followed	O
.	O

Although	O
a	O
causal	O
mechanism	O
and	O
a	O
cause-and-effect	O
relationship	O
have	O
not	O
been	O
established	O
,	O
current	O
evidence	O
suggests	O
that	O
renal	O
function	O
should	O
be	O
monitored	O
in	O
patients	O
on	O
thiazide	O
diuretics	O
and	O
allopurinol	B-Drug
even	O
in	O
the	O
absence	O
of	O
renal	O
failure	O
,	O
and	O
dosage	O
levels	O
should	O
be	O
even	O
more	O
conservatively	O
adjusted	O
in	O
those	O
patients	O
on	O
such	O
combined	O
therapy	O
if	O
diminished	O
renal	O
function	O
is	O
detected..	O
Ampicillin/Amoxicillin	B-Drug
:	O
An	O
increase	O
in	O
the	O
frequency	O
of	O
skin	O
rash	O
has	O
been	O
reported	O
among	O
patients	O
receiving	O
ampicillin	O
or	O
amoxicillin	O
concurrently	O
with	O
allopurinol	O
compared	O
to	O
patients	O
who	O
are	O
not	O
receiving	O
both	O
drugs	O
.	O

The	O
cause	O
of	O
the	O
reported	O
association	O
has	O
not	O
been	O
established	O
.	O

Cytotoxic	O
Agents	O
:	O
Enhanced	O
bone	O
marrow	O
suppression	O
by	O
cyclophosphamide	B-Drug
and	O
other	O
cytotoxic	O
agents	O
has	O
been	O
reported	O
among	O
patients	O
with	O
neoplastic	O
disease	O
,	O
except	O
leukemia	O
,	O
in	O
the	O
presence	O
of	O
allopurinol	B-Drug
.	O

However	O
,	O
in	O
a	O
well-controlled	O
study	O
of	O
patients	O
with	O
lymphoma	O
on	O
combination	O
therapy	O
,	O
allopurinol	B-Drug
did	O
not	O
increase	O
the	O
marrow	O
toxicity	O
of	O
patients	O
treated	O
with	O
cyclophosphamide	B-Drug
,	O
doxorubicin	B-Drug
,	O
bleomycin	B-Drug
,	O
procarbazine	B-Drug
and/or	O
mechlorethamine	B-Drug
.	O

Chlorpropamide	B-Drug
:	O
Chlorpropamides	B-Drug
plasma	O
half-life	O
may	O
be	O
prolonged	O
by	O
allopurinol	B-Drug
,	O
since	O
allopurinol	B-Drug
and	O
chlorpropamide	B-Drug
may	O
compete	O
for	O
excretion	O
in	O
the	O
renal	O
tubule	O
.	O

The	O
risk	O
of	O
hypoglycemia	O
secondary	O
to	O
this	O
mechanism	O
may	O
be	O
increased	O
if	O
allopurinol	B-Drug
and	O
chlorpropamide	B-Drug
are	O
given	O
concomitantly	O
in	O
the	O
presence	O
of	O
renal	O
insufficiency	O
.	O

Cyclosporin	B-Drug
:	O
Reports	O
indicate	O
that	O
cyclosporine	B-Drug
levels	O
may	O
be	O
increased	O
during	O
concomitant	O
treatment	O
with	O
allopurinol	B-Drug
sodium	I-Drug
for	O
injection	O
.	O

Monitoring	O
of	O
cyclosporine	B-Drug
levels	O
and	O
possible	O
adjustment	O
of	O
cyclosporine	B-Drug
dosage	O
should	O
be	O
considered	O
when	O
these	O
drugs	O
are	O
co-administered	O
.	O

Tolbutamides	B-Drug
conversion	O
to	O
inactive	O
metabolites	O
has	O
been	O
shown	O
to	O
be	O
catalyzed	O
by	O
xanthine	O
oxidase	O
from	O
rat	O
liver	O
.	O

The	O
clinical	O
significance	O
,	O
if	O
any	O
,	O
of	O
these	O
observations	O
is	O
unknown	O
.	O

Ergot-Containing	O
Drugs	O
:	O
These	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine-containing	B-Drug
or	O
ergot-type	O
medications	O
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
AXERT	B-Drug
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
.	O

Monoamine	O
Oxidase	O
Inhibitors	O
:	O
Coadministration	O
of	O
moclobemide	B-Drug
resulted	O
in	O
a	O
27	O
%	O
decrease	O
in	O
almotriptan	B-Drug
clearance	O
and	O
an	O
increase	O
in	O
Cmax	O
of	O
approximately	O
6	O
%	O
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Other	O
5-HT1B/1D	O
Agonists	O
Concomitant	O
use	O
of	O
other	O
5-HT1B/1D	O
agonists	O
within	O
24	O
hours	O
of	O
treatment	O
with	O
AXERT	B-Drug
is	O
contraindicated	O
.	O

Propanolol	B-Drug
:	O
The	O
pharmacokinetics	O
of	O
almotriptan	B-Drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
propranolol	B-Drug
.	O

Selective	O
Serotonin	O
Reuptake	O
Inhibitors	O
(	O
SSRIs	O
)	O
:	O
SSRIs	O
(	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
paroxetine	B-Drug
,	O
sertraline	B-Drug
)	O
have	O
been	O
rarely	O
reported	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5-HT1	O
agonists	O
.	O

If	O
concomitant	O
treatment	O
with	O
AXERT	B-Drug
and	O
an	O
SSRI	O
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Verapamil	B-Drug
:	O
Coadministration	O
of	O
almotriptan	B-Drug
and	O
verapamil	B-Drug
resulted	O
in	O
a	O
24	O
%	O
increase	O
in	O
plasma	O
concentrations	O
of	O
almotriptan	B-Drug
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Coadministration	O
of	O
almotriptan	B-Drug
and	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	B-Drug
(	O
400	O
mg	O
q.d	O
.	O

for	O
3	O
days	O
)	O
resulted	O
in	O
an	O
approximately	O
60	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
and	O
maximal	O
plasma	O
concentrations	O
of	O
almotriptan	B-Drug
.	O

Although	O
the	O
interaction	O
between	O
almotriptan	B-Drug
and	O
other	O
potent	O
CYP3A4	O
inhibitors	O
(	O
e.g.	O
,	O
itraconazole	B-Drug
,	O
ritonavir	B-Drug
,	O
and	O
erythromycin	B-Drug
)	O
has	O
not	O
been	O
studied	O
,	O
increased	O
exposures	O
to	O
almotriptan	B-Drug
may	O
be	O
expected	O
when	O
almotriptan	B-Drug
is	O
used	O
concomitantly	O
with	O
these	O
medications	O
.	O

AXERT	B-Drug
is	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O

Because	O
alosetron	B-Drug
is	O
metabolized	O
by	O
a	O
variety	O
of	O
hepatic	O
CYP	O
drug-metabolizing	O
enzymes	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
of	O
alosetron	B-Drug
.	O

Fluvoxamine	B-Drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP1A2	O
and	O
also	O
inhibits	O
CYP3A4	O
,	O
CYP2C9	O
,	O
and	O
CYP2C19	O
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
40	O
healthy	O
female	O
subjects	O
received	O
fluvoxamine	B-Drug
in	O
escalating	O
doses	O
from	O
50	O
to	O
200	O
mg	O
per	O
day	O
for	O
16	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B-Drug
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Fluvoxamine	B-Drug
increased	O
mean	O
alosetron	B-Drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
approximately	O
6-fold	O
and	O
prolonged	O
the	O
half-life	O
by	O
approximately	O
3-fold	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B-Drug
and	O
fluvoxamine	B-Drug
is	O
contraindicated	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B-Drug
and	O
moderate	O
CYP1A2	O
inhibitors	O
,	O
including	O
quinolone	O
antibiotics	O
and	O
cimetidine	B-Drug
,	O
has	O
not	O
been	O
evaluated	O
,	O
but	O
should	O
be	O
avoided	O
unless	O
clinically	O
necessary	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

Ketoconazole	B-Drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP3A4	O
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
38	O
healthy	O
female	O
subjects	O
received	O
ketoconazole	B-Drug
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B-Drug
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Ketoconazole	B-Drug
increased	O
mean	O
alosetron	B-Drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
by	O
29	O
%	O
.	O

Caution	O
should	O
be	O
used	O
when	O
alosetron	B-Drug
and	O
ketoconazole	B-Drug
are	O
administered	O
concomitantly	O
.	O

Coadministration	O
of	O
alosetron	B-Drug
and	O
strong	O
CYP3A4	O
inhibitors	O
,	O
such	O
as	O
clarithromycin	B-Drug
,	O
telithromycin	B-Drug
,	O
protease	O
inhibitors	O
,	O
voriconazole	B-Drug
,	O
and	O
itraconazole	B-Drug
has	O
not	O
been	O
evaluated	O
but	O
should	O
be	O
undertaken	O
with	O
caution	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

The	O
effect	O
of	O
induction	O
or	O
inhibition	O
of	O
other	O
pathways	O
on	O
exposure	O
to	O
alosetron	B-Drug
and	O
its	O
metabolites	O
is	O
not	O
known	O
.	O

In	O
vitro	O
human	O
liver	O
microsome	O
studies	O
and	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
demonstrated	O
that	O
alosetron	B-Drug
did	O
not	O
inhibit	O
CYP	O
enzymes	O
2D6	O
,	O
3A4	O
,	O
2C9	O
,	O
or	O
2C19	O
.	O

In	O
vitro	O
,	O
at	O
total	O
drug	O
concentrations	O
27-fold	O
higher	O
than	O
peak	O
plasma	O
concentrations	O
observed	O
with	O
the	O
1-mg	O
dosage	O
,	O
alosetron	B-Drug
inhibited	O
CYP	O
enzymes	O
1A2	O
(	O
60	O
%	O
)	O
and	O
2E1	O
(	O
50	O
%	O
)	O
.	O

In	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
,	O
alosetron	B-Drug
did	O
not	O
inhibit	O
CYP2E1	O
but	O
did	O
produce	O
30	O
%	O
inhibition	O
of	O
both	O
CYP1A2	O
and	O
N-acetyltransferase	O
.	O

Although	O
not	O
studied	O
with	O
alosetron	B-Drug
,	O
inhibition	O
of	O
N-acetyltransferase	O
may	O
have	O
clinically	O
relevant	O
consequences	O
for	O
drugs	O
such	O
as	O
isoniazid	B-Drug
,	O
procainamide	B-Drug
,	O
and	O
hydralazine	B-Drug
.	O

The	O
effect	O
on	O
CYP1A2	O
was	O
explored	O
further	O
in	O
a	O
clinical	O
interaction	O
study	O
with	O
theophylline	B-Drug
and	O
no	O
effect	O
on	O
metabolism	O
was	O
observed	O
.	O

Another	O
study	O
showed	O
that	O
alosetron	B-Drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
plasma	O
concentrations	O
of	O
the	O
oral	O
contraceptive	O
agents	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
(	O
CYP3A4	O
substrates	O
)	O
.	O

A	O
clinical	O
interaction	O
study	O
was	O
also	O
conducted	O
with	O
alosetron	B-Drug
and	O
the	O
CYP3A4	O
substrate	O
cisapride	B-Drug
.	O

No	O
significant	O
effects	O
on	O
cisapride	B-Drug
metabolism	O
or	O
QT	O
interval	O
were	O
noted	O
.	O

The	O
effect	O
of	O
alosetron	B-Drug
on	O
monoamine	O
oxidases	O
and	O
on	O
intestinal	O
first	O
pass	O
secondary	O
to	O
high	O
intraluminal	O
concentrations	O
have	O
not	O
been	O
examined	O
.	O

Based	O
on	O
the	O
above	O
data	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
,	O
it	O
is	O
unlikely	O
that	O
alosetron	B-Drug
will	O
inhibit	O
the	O
hepatic	O
metabolic	O
clearance	O
of	O
drugs	O
metabolized	O
by	O
the	O
major	O
CYP	O
enzyme	O
3A4	O
,	O
as	O
well	O
as	O
the	O
CYP	O
enzymes	O
2D6	O
,	O
2C9	O
,	O
2C19	O
,	O
2E1	O
,	O
or	O
1A2	O
.	O

Alosetron	B-Drug
does	O
not	O
appear	O
to	O
induce	O
the	O
major	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
drug	O
metabolizing	O
enzyme	O
3A	O
.	O

Alosetron	B-Drug
also	O
does	O
not	O
appear	O
to	O
induce	O
CYP	O
enzymes	O
2E1	O
or	O
2C19	O
.	O

It	O
is	O
not	O
known	O
whether	O
alosetron	B-Drug
might	O
induce	O
other	O
enzymes	O
.	O

The	O
benzodiazepines	O
,	O
including	O
alprazolam	B-Drug
,	O
produce	O
additive	O
CNS	O
depressant	O
effects	O
when	O
co-administered	O
with	O
other	O
psychotropic	O
medications	O
,	O
anticonvulsants	O
,	O
antihistaminics	O
,	O
ethanol	B-Drug
,	O
and	O
other	O
drugs	O
which	O
themselves	O
produce	O
CNS	O
depression	O
.	O

The	O
steady	O
state	O
plasma	O
concentrations	O
of	O
imipramine	B-Drug
and	O
desipramine	B-Drug
have	O
been	O
reported	O
to	O
be	O
increased	O
an	O
average	O
of	O
31	O
%	O
and	O
20	O
%	O
,	O
respectively	O
,	O
by	O
the	O
concomitant	O
administration	O
of	O
alprazolam	B-Drug
tablets	O
in	O
doses	O
up	O
to	O
4	O
mg/day	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
changes	O
is	O
unknown	O
.	O

Drugs	O
That	O
Inhibit	O
Alprazolam	B-Drug
Metabolism	O
Via	O
Cytochrome	O
P450	O
3A	O
:	O
The	O
initial	O
step	O
in	O
alprazolam	B-Drug
metabolism	O
is	O
hydroxylation	O
catalyzed	O
by	O
cytochrome	O
P450	O
3A	O
(	O
CYP	O
3A	O
)	O
.	O

Drugs	O
which	O
inhibit	O
this	O
metabolic	O
pathway	O
may	O
have	O
a	O
profound	O
effect	O
on	O
the	O
clearance	O
of	O
alprazolam	B-Drug
.	O

Drugs	O
Demonstrated	O
to	O
be	O
CYP	O
3A	O
Inhibitors	O
of	O
Possible	O
Clinical	O
Significance	O
on	O
the	O
Basis	O
of	O
Clinical	O
Studies	O
Involving	O
Alprazolam	B-Drug
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B-Drug
)	O
:	O
Coadministration	O
of	O
fluoxetine	B-Drug
with	O
alprazolam	B-Drug
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
46	O
%	O
,	O
decreased	O
clearance	O
by	O
21	O
%	O
,	O
increased	O
half-life	O
by	O
17	O
%	O
,	O
and	O
decreased	O
measured	O
psychomotor	O
performance	O
.	O

Coadministration	O
of	O
propoxyphene	B-Drug
decreased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
6	O
%	O
,	O
decreased	O
clearance	O
by	O
38	O
%	O
,	O
and	O
increased	O
half-life	O
by	O
58	O
%	O
.	O

Coadministration	O
of	O
oral	O
contraceptives	O
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
18	O
%	O
,	O
decreased	O
clearance	O
by	O
22	O
%	O
,	O
and	O
increased	O
half-life	O
by	O
29	O
%	O
.	O

Drugs	O
and	O
other	O
substances	O
demonstrated	O
to	O
be	O
CYP	O
3A	O
inhibitors	O
on	O
the	O
basis	O
of	O
clinical	O
studies	O
involving	O
benzodiazepines	O
metabolized	O
similarly	O
to	O
alprazolam	B-Drug
or	O
on	O
the	O
basis	O
of	O
in	O
vitro	O
studies	O
with	O
alprazolam	B-Drug
or	O
other	O
benzodiazepines	O
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B-Drug
)	O
:	O
Available	O
data	O
from	O
clinical	O
studies	O
of	O
benzodiazepines	O
other	O
than	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	B-Drug
for	O
the	O
following	O
:	O
diltiazem	B-Drug
,	O
isoniazid	B-Drug
,	O
macrolide	O
antibiotics	O
such	O
as	O
erythromycin	B-Drug
and	O
clarithromycin	B-Drug
,	O
and	O
grapefruit	O
juice	O
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	B-Drug
for	O
the	O
following	O
:	O
sertraline	B-Drug
and	O
paroxetine	B-Drug
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
benzodiazepines	O
other	O
than	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	O
interaction	O
for	O
the	O
following	O
:	O
ergotamine	B-Drug
,	O
cyclosporine	B-Drug
,	O
amiodarone	B-Drug
,	O
nicardipine	B-Drug
,	O
and	O
nifedipine	B-Drug
.	O

Caution	O
is	O
recommended	O
during	O
the	O
coadministration	O
of	O
any	O
of	O
these	O
with	O
alprazolam	B-Drug
.	O

No	O
drug	O
interactions	O
have	O
been	O
reported	O
between	O
Prostin	B-Drug
VR	I-Drug
Pediatric	I-Drug
and	O
the	O
therapy	O
standard	O
in	O
neonates	O
with	O
restricted	O
pulmonary	O
or	O
systemic	O
blood	O
flow	O
.	O

Standard	O
therapy	O
includes	O
antibiotics	O
,	O
such	O
as	O
penicillin	B-Drug
and	O
gentamicin	B-Drug
;	O
vasopressors	O
,	O
such	O
as	O
dopamine	B-Drug
and	O
isoproterenol	B-Drug
;	O
cardiac	O
glycosides	O
;	O
and	O
diuretics	O
,	O
such	O
as	O
furosemide	B-Drug
.	O

Caverject	B-Drug
:	O
The	O
potential	O
for	O
pharmacokinetic	O
drug-drug	O
interactions	O
between	O
alprostadil	B-Drug
and	O
other	O
agents	O
has	O
not	O
been	O
formally	O
studied	O
.	O

The	O
interaction	O
of	O
Activase	B-Drug
with	O
other	O
cardioactive	O
or	O
cerebroactive	O
drugs	O
has	O
not	O
been	O
studied	O
.	O

In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	B-Drug
and	O
vitamin	O
K	O
antagonists	O
,	O
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
dipyridamole	B-Drug
and	O
Abciximab	B-Drug
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
,	O
during	O
,	O
or	O
after	O
Activase	B-Drug
therapy	O
.	O

Use	O
of	O
Antithrombotics	O
Aspirin	B-Drug
and	O
heparin	B-Drug
have	O
been	O
administered	O
concomitantly	O
with	O
and	O
following	O
infusions	O
of	O
Activase	B-Drug
in	O
the	O
management	O
of	O
acute	O
myocardial	O
infarction	O
or	O
pulmonary	O
embolism	O
.	O

Because	O
heparin	B-Drug
,	O
aspirin	B-Drug
,	O
or	O
Activase	B-Drug
may	O
cause	O
bleeding	O
complications	O
,	O
careful	O
monitoring	O
for	O
bleeding	O
is	O
advised	O
,	O
especially	O
at	O
arterial	O
puncture	O
sites	O
.	O

The	O
concomitant	O
use	O
of	O
heparin	B-Drug
or	O
aspirin	B-Drug
during	O
the	O
first	O
24	O
hours	O
following	O
symptom	O
onset	O
were	O
prohibited	O
in	O
The	O
NINDS	O
t-PA	O
Stroke	O
Trial	O
.	O

The	O
safety	O
of	O
such	O
concomitant	O
use	O
with	O
Activase	B-Drug
for	O
the	O
management	O
of	O
acute	O
ischemic	O
stroke	O
is	O
unknown	O
.	O

Concurrent	O
administration	O
of	O
HEXALEN	B-Drug
and	O
antidepressants	O
of	O
the	O
MAO	O
inhibitor	O
class	O
may	O
cause	O
severe	O
orthostatic	O
hypotension.Cimetidine	B-Drug
,	O
an	O
inhibitor	O
of	O
microsomal	O
drug	O
metabolism	O
,	O
increased	O
altretamines	B-Drug
half-life	O
and	O
toxicity	O
in	O
a	O
rat	O
model	O
.	O

Data	O
from	O
a	O
randomized	O
trial	O
of	O
HEXALEN	B-Drug
and	O
cisplatin	B-Drug
plus	O
or	O
minus	O
pyridoxine	B-Drug
in	O
ovarian	O
cancer	O
indicated	O
that	O
pyridoxine	B-Drug
significantly	O
reduced	O
neurotoxicity	O
;	O
however	O
,	O
it	O
adversely	O
affected	O
response	O
duration	O
suggesting	O
that	O
pyridoxine	B-Drug
should	O
not	O
be	O
administered	O
with	O
HEXALEN	B-Drug
and/or	O
cisplatin.1	B-Drug
Careful	O
observation	O
is	O
required	O
when	O
amantadine	B-Drug
is	O
administered	O
concurrently	O
with	O
central	O
nervous	O
system	O
stimulants	O
.	O

Coadministration	O
of	O
thioridazine	B-Drug
has	O
been	O
reported	O
to	O
worsen	O
the	O
tremor	O
in	O
elderly	O
patients	O
with	O
Parkinsons	O
disease	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
if	O
other	O
phenothiazines	O
produce	O
a	O
similar	O
response	O
.	O

Special	O
consideration	O
should	O
be	O
given	O
to	O
the	O
administration	O
of	O
ETHYOL	B-Drug
in	O
patients	O
receiving	O
antihypertensive	O
medications	O
or	O
other	O
drugs	O
that	O
could	O
cause	O
or	O
potentiate	O
hypotension	O
.	O

When	O
amiloride	B-Drug
HCl	O
is	O
administered	O
concomitantly	O
with	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
,	O
the	O
risk	O
of	O
hyperkalemia	O
may	O
be	O
increased	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	O
.	O

Lithium	B-Drug
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	O
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	O
toxicity	O
.	O

Read	O
circulars	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non-steroidal	O
anti-inflammatory	O
agent	O
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	O
,	O
potassium-sparing	O
and	O
thiazide	O
diuretics	O
.	O

Therefore	O
,	O
when	O
MIDAMOR	B-Drug
and	O
non-steroidal	O
anti-inflammatory	O
agents	O
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	O
is	O
obtained	O
.	O

Since	O
indomethacin	B-Drug
and	O
potassium-sparing	O
diuretics	O
,	O
including	O
MIDAMOR	B-Drug
,	O
may	O
each	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
,	O
the	O
potential	O
effects	O
on	O
potassium	O
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Drug	O
Laboratory	O
Test	O
Interactions	O
:	O
Prolongation	O
of	O
the	O
template	O
bleeding	O
time	O
has	O
been	O
reported	O
during	O
continuous	O
intravenous	O
infusion	O
of	O
AMICAR	B-Drug
at	O
dosages	O
exceeding	O
24	O
g/day	O
.	O

Platelet	O
function	O
studies	O
in	O
these	O
patients	O
have	O
not	O
demonstrated	O
any	O
significant	O
platelet	O
dysfunction	O
.	O

However	O
,	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
at	O
high	O
concentrations	O
(	O
7.4	O
mMol/L	O
or	O
0.97	O
mg/mL	O
and	O
greater	O
)	O
EACA	B-Drug
inhibits	O
ADP	O
and	O
collagen-induced	O
platelet	O
aggregation	O
,	O
the	O
release	O
of	O
ATP	O
and	O
serotonin	O
,	O
and	O
the	O
binding	O
of	O
fibrinogen	O
to	O
the	O
platelets	O
in	O
a	O
concentration-response	O
manner	O
.	O

Following	O
a	O
10	O
g	O
bolus	O
of	O
AMICAR	B-Drug
,	O
transient	O
peak	O
plasma	O
concentrations	O
of	O
4.6	O
mMol/L	O
or	O
0.60	O
mg/mL	O
have	O
been	O
obtained	O
.	O

The	O
concentration	O
of	O
AMICAR	B-Drug
necessary	O
to	O
maintain	O
inhibition	O
of	O
fibrinolysis	O
is	O
0.99	O
mMol/L	O
or	O
0.13	O
mg/mL	O
.	O

Administration	O
of	O
a	O
5	O
g	O
bolus	O
followed	O
by	O
1	O
to	O
1.25	O
g/hr	O
should	O
achieve	O
and	O
sustain	O
plasma	O
levels	O
of	O
0.13	O
mg/mL	O
.	O

Thus	O
,	O
concentrations	O
which	O
have	O
been	O
obtained	O
in	O
vivo	O
clinically	O
in	O
patients	O
with	O
normal	O
renal	O
function	O
are	O
considerably	O
lower	O
than	O
the	O
in	O
vitro	O
concentrations	O
found	O
to	O
induce	O
abnormalities	O
in	O
platelet	O
function	O
tests	O
.	O

However	O
,	O
higher	O
plasma	O
concentrations	O
of	O
AMICAR	B-Drug
may	O
occur	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
.	O

Cytadren	B-Drug
accelerates	O
the	O
metabolism	O
of	O
dexamethasone	B-Drug
;	O
therefore	O
,	O
if	O
glucocorticoid	O
replacement	O
is	O
needed	O
,	O
hydrocortisone	B-Drug
should	O
be	O
prescribed	O
.	O

Aminoglutethimide	B-Drug
diminishes	O
the	O
effect	O
of	O
coumarin	O
and	O
warfarin	B-Drug
.	O

Renal	O
clearance	O
measurements	O
of	O
PAH	B-Drug
can	O
not	O
be	O
made	O
with	O
any	O
significant	O
accuracy	O
in	O
patients	O
receiving	O
sulfonamides	O
,	O
procaine	B-Drug
,	O
or	O
thiazolesulfone	B-Drug
.	O

These	O
compounds	O
interfere	O
with	O
chemical	O
color	O
development	O
essential	O
to	O
the	O
analytical	O
procedures	O
.	O

Probenecid	B-Drug
depresses	O
tubular	O
secretion	O
of	O
certain	O
weak	O
acids	O
such	O
as	O
PAH	B-Drug
.	O

Therefore	O
,	O
patients	O
receiving	O
probenecid	B-Drug
will	O
have	O
erroneously	O
low	O
ERPF	O
and	O
Tm	O
PAH	B-Drug
values	O
.	O

There	O
have	O
been	O
no	O
formal	O
studies	O
of	O
the	O
interaction	O
of	O
LEVULAN	B-Drug
KERASTICK	I-Drug
for	O
Topical	O
Solution	O
with	O
any	O
other	O
drugs	O
,	O
and	O
no	O
drug-specific	O
interactions	O
were	O
noted	O
during	O
any	O
of	O
the	O
controlled	O
clinical	O
trials	O
.	O

It	O
is	O
,	O
however	O
,	O
possible	O
that	O
concomitant	O
use	O
of	O
other	O
known	O
photosensitizing	O
agents	O
such	O
as	O
griseofulvin	B-Drug
,	O
thiazide	O
diuretics	O
,	O
sulfonylureas	O
,	O
phenothiazines	O
,	O
sulfonamides	O
and	O
tetracyclines	O
might	O
increase	O
the	O
photosensitivity	O
reaction	O
of	O
actinic	O
keratoses	O
treated	O
with	O
the	O
LEVULAN	B-Drug
KERASTICK	I-Drug
for	O
Topical	O
Solution	O
.	O

Aminosalicylic	B-Drug
acid	I-Drug
may	O
decrease	O
the	O
amount	O
of	O
digoxin	B-Drug
(	O
Lanoxin	B-Drug
,	O
Lanoxicaps	B-Drug
)	O
that	O
gets	O
absorbed	O
into	O
your	O
body	O
.	O

In	O
the	O
case	O
that	O
you	O
are	O
taking	O
digoxin	B-Drug
while	O
taking	O
aminosalicylic	B-Drug
acid	I-Drug
,	O
higher	O
doses	O
of	O
digoxin	B-Drug
may	O
be	O
needed	O
.	O

Aminosalicylic	B-Drug
acid	I-Drug
may	O
also	O
decrease	O
the	O
absorption	O
of	O
vitamin	B-Drug
B12	I-Drug
,	O
which	O
can	O
lead	O
to	O
a	O
deficiency	O
.	O

Therefore	O
you	O
may	O
need	O
to	O
take	O
a	O
vitamin	B-Drug
B12	I-Drug
supplement	O
while	O
taking	O
aminosalicylic	B-Drug
acid	I-Drug
.	O

Amiodarone	B-Drug
is	O
metabolized	O
to	O
desethylamiodarone	B-Drug
by	O
the	O
cytochrome	O
P450	O
(	O
CYP450	O
)	O
enzyme	O
group	O
,	O
specifically	O
cytochromes	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
and	O
CYP2C8	O
.	O

The	O
CYP3A4	O
isoenzyme	O
is	O
present	O
in	O
both	O
the	O
liver	O
and	O
intestines	O
.	O

Amiodarone	B-Drug
is	O
also	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
CYP3A4	O
.	O

Therefore	O
,	O
amiodarone	B-Drug
has	O
the	O
potential	O
for	O
interactions	O
with	O
drugs	O
or	O
substances	O
that	O
may	O
be	O
substrates	O
,	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	O
.	O

While	O
only	O
a	O
limited	O
number	O
of	O
in	O
vivo	O
drug-drug	O
interactions	O
with	O
amiodarone	B-Drug
have	O
been	O
reported	O
,	O
chiefly	O
with	O
the	O
oral	O
formulation	O
,	O
the	O
potential	O
for	O
other	O
interactions	O
should	O
be	O
anticipated	O
.	O

This	O
is	O
especially	O
important	O
for	O
drugs	O
associated	O
with	O
serious	O
toxicity	O
,	O
such	O
as	O
other	O
antiarrhythmics	O
.	O

If	O
such	O
drugs	O
are	O
needed	O
,	O
their	O
dose	O
should	O
be	O
reassessed	O
and	O
,	O
where	O
appropriate	O
,	O
plasma	O
concentration	O
measured	O
.	O

In	O
view	O
of	O
the	O
long	O
and	O
variable	O
half-life	O
of	O
amiodarone	B-Drug
,	O
potential	O
for	O
drug	O
interactions	O
exists	O
not	O
only	O
with	O
concomitant	O
medication	O
but	O
also	O
with	O
drugs	O
administered	O
after	O
discontinuation	O
of	O
amiodarone	B-Drug
.	O

Since	O
amiodarone	B-Drug
is	O
a	O
substrate	O
for	O
CYP3A4	O
and	O
CYP2C8	O
,	O
drugs/substances	O
that	O
inhibit	O
these	O
isoenzymes	O
may	O
decrease	O
the	O
metabolism	O
and	O
increase	O
serum	O
concentration	O
of	O
amiodarone	B-Drug
.	O

Reported	O
examples	O
include	O
the	O
following	O
:	O
Protease	O
Inhibitors	O
:	O
Protease	O
inhibitors	O
are	O
known	O
to	O
inhibit	O
CYP3A4	O
to	O
varying	O
degrees	O
.	O

A	O
case	O
report	O
of	O
one	O
patient	O
taking	O
amiodarone	B-Drug
200	O
mg	O
and	O
indinavir	B-Drug
800	O
mg	O
three	O
times	O
a	O
day	O
resulted	O
in	O
increases	O
in	O
amiodarone	B-Drug
concentrations	O
from	O
0.9	O
mg/L	O
to	O
1.3	O
mg/L	O
.	O

DEA	O
concentrations	O
were	O
not	O
affected	O
.	O

There	O
was	O
no	O
evidence	O
of	O
toxicity	O
.	O

Monitoring	O
for	O
amiodarone	B-Drug
toxicity	O
and	O
serial	O
measurement	O
of	O
amiodarone	B-Drug
serum	O
concentration	O
during	O
concomitant	O
protease	O
inhibitor	O
therapy	O
should	O
be	O
considered	O
.	O

Histamine	O
H2	O
antagonists	O
:	O
Cimetidine	B-Drug
inhibits	O
CYP3A4	O
and	O
can	O
increase	O
serum	O
amiodarone	B-Drug
levels	O
.	O

Other	O
substances	O
:	O
Grapefruit	O
juice	O
given	O
to	O
healthy	O
volunteers	O
increased	O
amiodarone	B-Drug
AUC	O
by	O
50	O
%	O
and	O
Cmax	O
by	O
84	O
%	O
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
amiodarone	B-Drug
.	O

Grapefruit	O
juice	O
should	O
not	O
be	O
taken	O
during	O
treatment	O
with	O
oral	O
amiodarone	O
.	O

This	O
information	O
should	O
be	O
considered	O
when	O
changing	O
from	O
intravenous	O
amiodarone	B-Drug
to	O
oral	O
amiodarone	B-Drug
.	O

Amiodarone	B-Drug
may	O
suppress	O
certain	O
CYP450	O
enzymes	O
,	O
including	O
CYP1A2	B-Drug
,	O
CYP2C9	B-Drug
,	O
CYP2D6	B-Drug
,	O
and	O
CYP3A4	B-Drug
.	O

This	O
inhibition	O
can	O
result	O
in	O
unexpectedly	O
high	O
plasma	O
levels	O
of	O
other	O
drugs	B-Drug
which	O
are	O
metabolized	O
by	O
those	O
CYP450	O
enzymes	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Immunosuppressives	B-Drug
:	O
Cyclosporine	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
administered	O
in	O
combination	O
with	O
oral	O
amiodarone	B-Drug
has	O
been	O
reported	O
to	O
produce	O
persistently	O
elevated	O
plasma	O
concentrations	O
of	O
cyclosporine	B-Drug
resulting	O
in	O
elevated	O
creatinine	O
,	O
despite	O
reduction	O
in	O
dose	O
of	O
cyclosporine	B-Drug
.	O

HMG-CoA	B-Drug
Reductase	I-Drug
Inhibitors	I-Drug
:	O
Simvastatin	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-Drug
has	O
been	O
associated	O
with	O
reports	O
of	O
myopathy/rhabdomyolysis	O
.	O

Cardiovasculars	O
:	O
Cardiac	B-Drug
glycosides	I-Drug
:	O
In	O
patients	O
receiving	O
digoxin	B-Drug
therapy	O
,	O
administration	O
of	O
oral	O
amiodarone	B-Drug
regularly	O
results	O
in	O
an	O
increase	O
in	O
serum	O
digoxin	B-Drug
concentration	O
that	O
may	O
reach	O
toxic	O
levels	O
with	O
resultant	O
clinical	O
toxicity	O
.	O

Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
digoxin	B-Drug
increases	O
the	O
serum	O
digoxin	B-Drug
concentration	O
by	O
70	O
%	O
after	O
one	O
day	O
.	O

On	O
administration	O
of	O
oral	O
amiodarone	B-Drug
,	O
the	O
need	O
for	O
digitalis	O
therapy	O
should	O
be	O
reviewed	O
and	O
the	O
dose	O
reduced	O
by	O
approximately	O
50	O
%	O
or	O
discontinued	O
.	O

If	O
digitalis	B-Drug
treatment	O
is	O
continued	O
,	O
serum	O
levels	O
should	O
be	O
closely	O
monitored	O
and	O
patients	O
observed	O
for	O
clinical	O
evidence	O
of	O
toxicity	O
.	O

These	O
precautions	O
probably	O
should	O
apply	O
to	O
digitoxin	B-Drug
administration	O
as	O
well	O
.	O

Antiarrhythmics	B-Drug
:	O
Other	O
antiarrhythmic	B-Drug
drugs	O
,	O
such	O
as	O
quinidine	B-Drug
,	O
procainamide	B-Drug
,	O
disopyramide	B-Drug
,	O
and	O
phenytoin	B-Drug
,	O
have	O
been	O
used	O
concurrently	O
with	O
amiodarone	B-Drug
.	O

There	O
have	O
been	O
case	O
reports	O
of	O
increased	O
steady-state	O
levels	O
of	O
quinidine	B-Drug
,	O
procainamide	B-Drug
,	O
and	O
phenytoin	B-Drug
during	O
concomitant	O
therapy	O
with	O
amiodarone	B-Drug
.	O

Phenytoin	B-Drug
decreases	O
serum	O
amiodarone	O
levels	O
.	O

Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
quinidine	B-Drug
increases	O
quinidine	B-Drug
serum	O
concentration	O
by	O
33	O
%	O
after	O
two	O
days	O
.	O

Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
procainamide	B-Drug
for	O
less	O
than	O
seven	O
days	O
increases	O
plasma	O
concentrations	O
of	O
procainamide	B-Drug
and	O
n-acetyl	O
procainamide	B-Drug
by	O
55	O
%	O
and	O
33	O
%	O
,	O
respectively	O
.	O

Quinidine	B-Drug
and	O
procainamide	O
doses	O
should	O
be	O
reduced	O
by	O
one-third	O
when	O
either	O
is	O
administered	O
with	O
amiodarone	B-Drug
.	O

Plasma	O
levels	O
of	O
flecainide	B-Drug
have	O
been	O
reported	O
to	O
increase	O
in	O
the	O
presence	O
of	O
oral	O
amiodarone	B-Drug
;	O
because	O
of	O
this	O
,	O
the	O
dosage	O
of	O
flecainide	B-Drug
should	O
be	O
adjusted	O
when	O
these	O
drugs	B-Drug
are	O
administered	O
concomitantly	O
.	O

In	O
general	O
,	O
any	O
added	O
antiarrhythmic	B-Drug
drug	I-Drug
should	O
be	O
initiated	O
at	O
a	O
lower	O
than	O
usual	O
dose	O
with	O
careful	O
monitoring	O
.	O

Combination	O
of	O
amiodarone	B-Drug
with	O
other	O
antiarrhythmic	B-Drug
therapy	O
should	O
be	O
reserved	O
for	O
patients	O
with	O
life-threatening	O
ventricular	O
arrhythmias	O
who	O
are	O
incompletely	O
responsive	O
to	O
a	O
single	O
agent	O
or	O
incompletely	O
responsive	O
to	O
amiodarone	B-Drug
.	O

During	O
transfer	O
to	O
oral	O
amiodarone	B-Drug
,	O
the	O
dose	O
levels	O
of	O
previously	O
administered	O
agents	O
should	O
be	O
reduced	O
by	O
30	O
to	O
50	O
%	O
several	O
days	O
after	O
the	O
addition	O
of	O
oral	O
amiodarone	B-Drug
.	O

The	O
continued	O
need	O
for	O
the	O
other	O
antiarrhythmic	B-Drug
agent	O
should	O
be	O
reviewed	O
after	O
the	O
effects	O
of	O
amiodarone	B-Drug
have	O
been	O
established	O
,	O
and	O
discontinuation	O
ordinarily	O
should	O
be	O
attempted	O
.	O

If	O
the	O
treatment	O
is	O
continued	O
,	O
these	O
patients	O
should	O
be	O
particularly	O
carefully	O
monitored	O
for	O
adverse	O
effects	O
,	O
especially	O
conduction	O
disturbances	O
and	O
exacerbation	O
of	O
tachyarrhythmias	O
,	O
as	O
amiodarone	B-Drug
is	O
continued	O
.	O

In	O
amiodarone-treated	B-Drug
patients	O
who	O
require	O
additional	O
antiarrhythmic	B-Drug
therapy	O
,	O
the	O
initial	O
dose	O
of	O
such	O
agents	O
should	O
be	O
approximately	O
half	O
of	O
the	O
usual	O
recommended	O
dose	O
.	O

Antihypertensives	B-Drug
:	O
Amiodarone	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
-receptor	B-Drug
blocking	O
agents	O
(	O
e.g.	O
,	O
propranolol	B-Drug
,	O
a	O
CYP3A4	B-Drug
inhibitor	O
)	O
or	O
calcium	B-Drug
channel	I-Drug
antagonists	O
(	O
e.g.	O
,	O
verapamil	B-Drug
,	O
a	O
CYP3A4	B-Drug
substrate	O
,	O
and	O
diltiazem	B-Drug
,	O
a	O
CYP3A4	B-Drug
inhibitor	O
)	O
because	O
of	O
the	O
possible	O
potentiation	O
of	O
bradycardia	O
,	O
sinus	O
arrest	O
,	O
and	O
AV	O
block	O
;	O
if	O
necessary	O
,	O
amiodarone	B-Drug
can	O
continue	O
to	O
be	O
used	O
after	O
insertion	O
of	O
a	O
pacemaker	O
in	O
patients	O
with	O
severe	O
bradycardia	O
or	O
sinus	O
arrest	O
.	O

Anticoagulants	B-Drug
:	O
Potentiation	O
of	O
warfarin-type	B-Drug
(	O
CYP2C9	B-Drug
and	O
CYP3A4	B-Drug
substrate	O
)	O
anticoagulant	B-Drug
response	O
is	O
almost	O
always	O
seen	O
in	O
patients	O
receiving	O
amiodarone	B-Drug
and	O
can	O
result	O
in	O
serious	O
or	O
fatal	O
bleeding	O
.	O

Since	O
the	O
concomitant	O
administration	O
of	O
warfarin	B-Drug
with	O
amiodarone	B-Drug
increases	O
the	O
prothrombin	O
time	O
by	O
100	O
%	O
after	O
3	O
to	O
4	O
days	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	B-Drug
should	O
be	O
reduced	O
by	O
one-third	O
to	O
one-half	O
,	O
and	O
prothrombin	O
times	O
should	O
be	O
monitored	O
closely	O
.	O

Some	O
drugs/substances	B-Drug
are	O
known	O
to	O
accelerate	O
the	O
metabolism	O
of	O
amiodarone	B-Drug
by	O
stimulating	O
the	O
synthesis	O
of	O
CYP3A4	B-Drug
(	O
enzyme	O
induction	O
)	O
.	O

This	O
may	O
lead	O
to	O
low	O
amiodarone	B-Drug
serum	O
levels	O
and	O
potential	O
decrease	O
in	O
efficacy	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Antibiotics	B-Drug
:	O
Rifampin	B-Drug
is	O
a	O
potent	O
inducer	O
of	O
CYP3A4	B-Drug
.	O

Administration	O
of	O
rifampin	B-Drug
concomitantly	O
with	O
oral	O
amiodarone	B-Drug
has	O
been	O
shown	O
to	O
result	O
in	O
decreases	O
in	O
serum	O
concentrations	O
of	O
amiodarone	B-Drug
and	O
desethylamiodarone	B-Drug
.	O

Other	O
substances	O
,	O
including	O
herbal	O
preparations	O
:	O
St.	O
John	O
s	O
Wort	O
(	O
Hypericum	O
perforatum	O
)	O
induces	O
CYP3A4	O
.	O

Since	O
amiodarone	B-Drug
is	O
a	O
substrate	O
for	O
CYP3A4	B-Drug
,	O
there	O
is	O
the	O
potential	O
that	O
the	O
use	O
of	O
St.	O
John	O
s	O
Wort	O
in	O
patients	O
receiving	O
amiodarone	B-Drug
could	O
result	O
in	O
reduced	O
amiodarone	B-Drug
levels	O
.	O

Other	O
reported	O
interactions	O
with	O
amiodarone	B-Drug
:	O
Fentanyl	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-Drug
may	O
cause	O
hypotension	O
,	O
bradycardia	O
,	O
and	O
decreased	O
cardiac	O
output	O
.	O

Sinus	O
bradycardia	O
has	O
been	O
reported	O
with	O
oral	O
amiodarone	B-Drug
in	O
combination	O
with	O
lidocaine	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
given	O
for	O
local	O
anesthesia	B-Drug
.	O

Seizure	O
,	O
associated	O
with	O
increased	O
lidocaine	B-Drug
concentrations	O
,	O
has	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
intravenous	O
amiodarone	B-Drug
.	O

Dextromethorphan	B-Drug
is	O
a	O
substrate	O
for	O
both	O
CYP2D6	B-Drug
and	O
CYP3A4	B-Drug
.	O

Amiodarone	B-Drug
inhibits	O
CYP2D6	B-Drug
.	O

Cholestyramine	B-Drug
increases	O
enterohepatic	O
elimination	O
of	O
amiodarone	B-Drug
and	O
may	O
reduce	O
its	O
serum	O
levels	O
and	O
t1/2	B-Drug
.	O

Disopyramide	B-Drug
increases	O
QT	O
prolongation	O
which	O
could	O
cause	O
arrhythmia	O
.	O

Fluoroquinolones	B-Drug
,	O
macrolide	B-Drug
antibiotics	I-Drug
,	O
and	O
azoles	O
are	O
known	O
to	O
cause	O
QTc	O
prolongation	O
.	O

There	O
have	O
been	O
reports	O
of	O
QTc	O
prolongation	O
,	O
with	O
or	O
without	O
TdP	O
,	O
in	O
patients	O
taking	O
amiodarone	B-Drug
when	O
fluoroquinolones	B-Drug
,	O
macrolide	B-Drug
antibiotics	I-Drug
,	O
or	O
azoles	O
were	O
administered	O
concomitantly	O
.	O

Hemodynamic	O
and	O
electrophysiologic	O
interactions	O
have	O
also	O
been	O
observed	O
after	O
concomitant	O
administration	O
with	O
propranolol	B-Drug
,	O
diltiazem	B-Drug
,	O
and	O
verapamil	B-Drug
.	O

Volatile	O
Anesthetic	B-Drug
Agents	O
:	O
.	O

In	O
addition	O
to	O
the	O
interactions	O
noted	O
above	O
,	O
chronic	O
(	O
2	O
weeks	O
)	O
oral	O
Cordarone	B-Drug
administration	O
impairs	O
metabolism	O
of	O
phenytoin	B-Drug
,	O
dextromethorphan	B-Drug
,	O
and	O
methotrexate	B-Drug
.	O

Electrolyte	O
Disturbances	O
Patients	O
with	O
hypokalemia	O
or	O
hypomagnesemia	O
should	O
have	O
the	O
condition	O
corrected	O
whenever	O
possible	O
before	O
being	O
treated	O
with	O
Cordarone	B-Drug
I.V.	I-Drug
,	O
as	O
these	O
disorders	O
can	O
exaggerate	O
the	O
degree	O
of	O
QTc	O
prolongation	O
and	O
increase	O
the	O
potential	O
for	O
TdP	O
.	I-Drug
Special	O
attention	O
should	O
be	O
given	O
to	O
electrolyte	O
and	O
acid-base	O
balance	O
in	O
patients	O
experiencing	O
severe	O
or	O
prolonged	O
diarrhea	O
or	O
in	O
patients	O
receiving	O
concomitant	O
diuretics	B-Drug
.	O

Drugs	O
Metabolized	O
by	O
P450	O
2D6	O
-	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7-10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	O
antidepressants	O
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8-fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	O
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	O
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	O
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	O
,	O
phenothiazines	O
,	O
and	O
the	O
Type	O
1C	O
antiarrhythmics	O
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
sertraline	B-Drug
,	O
and	O
paroxetine	B-Drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

